

# European Foundation for the Study of Diabetes

The Research Foundation of the European Association for the Study of Diabetes

## Invitation to submit Letters of Intent (LOI)

European Foundation for the Study of Diabetes (EFSD)

and

Pfizer Inc.

## ANNOUNCING UP TO EURO 200,000 FOR THE CREATION OF ONE OR MORE RESOURCES TO FACILITATE DIABETES RESEARCH IN EUROPE

### Background

The European Association for the Study of Diabetes (EASD) was founded in Montecatini, Italy in 1965. In 1999, the Association created the *European Foundation for the Study of Diabetes (EFSD)*. The aims of EFSD are to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge and to facilitate its application.

**Pfizer** is one of the world's leading healthcare companies, providing human and animal pharmaceuticals, as well as consumer products. With a portfolio that includes five of the world's 20 top-selling medicines, Pfizer is helping to improve the lives of people the world over.

### Plan and goals

EFSD and Pfizer will partner, with a view to funding in 2004, one or more *EFSD / Pfizer Resource Awards for European Diabetes Research*. The total amount available will be € 200,000. The aim of the(se) award(s) is to allow for development of a *resource for diabetes research*, which will be available on an open-access basis or at nominal cost to all researchers in the field in Europe. Examples might be products for research (e.g. gene microarrays), biological material (e.g. cell lines), a database or co-ordination and integration of samples / data from ongoing multi-centre endeavours (i.e. genetic screening). This list is *not intended to be complete* and other proposals will be welcome as long as any proposed resource is evident-

ly relevant to the study of diabetes and its complications.

### Letter of Intent procedure

In order to identify projects suitable for funding, the partnership is inviting interested individuals, groups of individuals or institutions to submit a **LETTER OF INTENT** describing in *not more than 2 pages* the features of the proposed resource, its potential importance in facilitating diabetes research in Europe and an outline budget.

Letters of Intent will be reviewed by an independent *ad hoc panel of experts*.

**Upon invitation only**, those deemed of particular interest will be considered for funding further to submission of a **full application for competitive review**. Details of the procedure will be made available to those receiving this specific invitation to submit a full application.

### Electronic submission of Letters of Intent

*Letters of Intent will only be considered if submitted electronically.*

Letters of Intent should be submitted by **3 May 2004** as a *Word file attached to an e-mail*. The e-mail should be addressed to:

foundation@easd.org

Please mention "EFSD / Pfizer LOI" in the subject box.

## Enquiries

All written enquiries should be addressed to: foundation@easd.org. Please put "EFSD / Pfizer enquiry" in the subject box.

Telephone enquiries may be made to: Dr Viktor Jörgens, Executive Director of EFSD on: + 49 211 75 84 69 0

## Schedule

<b>Announcement:</b>	March issue of <i>Diabetologia</i>
<b>Deadline for Letters of Intent (LOIs):</b>	3 May 2004
<b>Invitations to submit full application:</b>	20 May 2004
<b>Deadline for full applications:</b>	1 August 2004
<b>Anticipated start of award:</b>	September 2004

**EASD****EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES**

ASSOCIATION EUROPEENE POUR L'ETUDE DU DIABETE · EUROPÄISCHE GESELLSCHAFT FÜR DIABETOLOGIE

Rheindorfer Weg 3 · D-40591 Düsseldorf · Germany · Tel: +49-211-7 58 46 90 · Fax: +49-211-75 84 69 29

E-mail: secretariat@easd.org · Homepage: <http://www.easd.org>**EASD****News Section  
3/2004**

## **Minutes of the EASD Diabetes Neuropathy Study Group (NEURODIAB) General Assembly**

### **Saint Malo, France, 2 September 2003**

About 20 members attended the General Assembly

- Paul Valensi was cordially thanked for a well-organised meeting.
- The current meeting was discussed. There was no joint meeting with the Diabetic Foot Study Group of the EASD in 2003. There will be a joint meeting in 2004. The question regarding joint meetings beyond 2005 is open. A certain scepticism regarding future joint meetings was noted in the audience. To increase the interest for the General Assembly, it was suggested that it should be included in the middle of the program and not at the end.
- Dr Paul Valensi was elected as the new chairman. Dr Vincenza Spallone, Dr Peter Kempler and Dr Solomon Tesfaye were elected to succeed Drs Dan Ziegler, Johannes Jacobsen and Göran Sundkvist who had served their time in the Executive Committee.
- The next meeting will be held in Regensburg, Bavaria, Germany. There will be a joint symposium with the Foot Study Group of the EASD. The proposed program is as follows: NEURODIAB starts

on 2 September 2004 with a combined symposium with the Foot Study Group. Then NEURODIAB continues on 3–4 September to end with departure on 5 September. Social events will include a Welcome reception and a Farewell dinner.

- The meeting in 2005 will be in Greece and will not be a joint meeting with the Foot Study Group. The location may be a Greek island. However, it is important that the selected location is easily reached by air.
- For financial reasons, it might be that in the future NEURODIAB will only support presenters and not all members attending NEURODIAB meetings.
- There are some plans for the introduction of new diabetic neuropathy guidelines by NEURODIAB, perhaps supported by Lilly.
- Dr Ziegler was thanked for his dedication and contributions during the years when he served as chairman of NEURODIAB.
- The General Assembly was brought to a close.

Göran Sundkvist and Paul Valensi

## Announcements

### **14th Annual Meeting EASD Diabetes Neuropathy Study Group (NEURODIAB)**

Regensburg, Germany, 2–5 September 2004

This meeting will be held in conjunction with the Diabetic Foot Study Group of the EASD in Regensburg, Germany, 2–5 September 2004, before the EASD Annual Meeting in Munich. Regensburg is located less than 100 km from Munich.

This symposium aims to give physicians and researchers the opportunity to exchange their views and ideas on the mechanisms underlying the various neuropathic complications and to discuss how they could be detected at their earliest stages and most effectively treated or prevented.

Abstracts are invited from clinicians or basic scientists with an interest in the various areas of diabetic neuropathies. Oral and poster communications will be reviewed and selected by the Executive Committee of NEURODIAB.

In addition to a productive scientific programme, social activities in the beautiful town of Regensburg are planned.

For all matters regarding registration, accommodation, travel and abstract submission please go to [www.neurodiab.org](http://www.neurodiab.org)

### **35th Annual Meeting of the EASD Diabetic Pregnancy Study Group (DPSG)**

Luso, Portugal, 9–12 September 2004

The meeting will take place at Luso Hotel, which is located in the Luso village, a spa near Bussaco hill and the city of Coimbra.

The deadline for abstract submission is **16 April 2004**.

*For further information please visit the DPSG home page:*

[www.dpsg.nu](http://www.dpsg.nu)

or contact the local organiser:

Manuela Carvalheiro

Tel: +351-239-400423

Fax: +351-239-825879

E-mail: [carvalheiro@huc.min-saude.pt](mailto:carvalheiro@huc.min-saude.pt) or  
[macarvalheiro@clix.pt](mailto:macarvalheiro@clix.pt) (home)

### **9th International Symposium on Insulin Receptors and Insulin Action**

Nice, France, 14–17 October 2004

*Please consult the website for further information:*

<http://ir04.iso-intl.com>

The complete scientific programme will be available on this site in the near future.

Emmanuel Van Obberghen, MD, PhD  
President of the Symposium and  
Chairman of the Local Organising Committee  
Tel: + 33-4-93815447  
Fax: + 33-4-93815432  
E-mail: [vanobbeg@unice.fr](mailto:vanobbeg@unice.fr)

### **The Immunology of Diabetes II: Pathogenesis from Mouse to Man Edited by C.B. Sanjeevi and G.S. Eisenbarth**

This book summarises the 6th International Congress of the Immunology of Diabetes Society and American Diabetes Association Research Symposium, Copper Mountain, Colorado, 3–6 October 2002. Members of the Immunology of Diabetes Society (IDS), American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) are entitled to a 20% discount on the cover price.

The contents of the volume can be seen on the following website:

<http://www.annalsnyas.org/content/vol1005/issue1/>

*For more information on ordering, please contact:*

**Katherine Traxler Goldring**  
Director of Marketing and Membership  
New York Academy of Sciences  
2 East 63rd Street  
New York, NY 10021  
USA

EASD News Section 3/2004  
DOI 10.1007/s00125-004-1353-3